In this episode, Esther Sánchez, Associate Director of the Global Start-Up Unit at Indero, brings more than 24 years of experience in clinical research to our discussion. Esther provides expert perspective on the vital role of a strong startup team in clinical trials, shares the key factors that contribute to team effectiveness, and highlights strategies for avoiding common pitfalls in the startup process. Listen for actionable insights to elevate your clinical trial outcomes.
The Essential Role of a Robust Startup Unit in Clinical Trials
Establishing a robust startup unit is fundamental to clinical trial success. The startup phase determines whether timelines are protected or lost, risks are anticipated or overlooked, and critical relationships with sites and sponsors are properly managed. A strong startup team ensures efficient execution of essential activities such as regulatory submission, site activation, and contract execution. Clear understanding of local requirements and strategic oversight are necessary to address country-specific challenges and flag feasibility concerns early. Close alignment with clinical operations, regulatory functions, and sponsors reduces delays, minimizes amendments, and supports confident enrollment progression. Excellence in startup operations accelerates site activation, enables earlier first patient in, improves enrollment projections, and enhances data quality throughout the trial.
Startup Teams: Warriors on the Front Lines
The startup phase in clinical trials serves as the operational front line, distinguished by its complexity and intense pressure. During this stage, multiple stakeholders, demanding timelines, regulatory requirements, and competing priorities all converge, creating a challenging environment that demands exceptional coordination. Achieving success in this phase hinges on the team’s resilience, adaptability, and proactive, solution-oriented mindset.
Teams must skillfully navigate regulatory hurdles, negotiate budgets and contracts, address site-specific challenges, and manage unexpected last-minute changes. To keep study timelines on track, it is essential to anticipate potential obstacles and resolve problems swiftly as they arise. Ultimately, effective performance in this critical phase requires a sense of ownership and advocacy for the goals of the study, sites, and sponsors while maintaining a careful balance between company needs, a sense of urgency, and unwavering commitment to quality.
Essential Startup Process Checks for Every Company
Cross-functional collaboration is essential for clinical trial startup success. This collaboration must include both internal teams and sponsors, functioning as a unified group. By integrating feasibility, site identification, regulatory, contract, and clinical functions within a shared framework, teams can leverage collective expertise to efficiently navigate complex regulatory environments. Optimal activation strategies depend on genuine partnership with sponsors and internal stakeholders, which fosters active listening, adaptability, and the co-creation of solutions. Each startup brings its own unique challenges, making it essential to develop tailored strategies and maintain clear alignment with client priorities.
Effective cross-functional collaboration hinges on treating sponsors as true partners, ensuring consistent communication and shared goals. Building on this foundation, proactive risk management is crucial; early identification and mitigation of risks help prevent delays and reduce rework or missed milestones in contracts, regulatory documents, and submissions. Accountability and ownership are key, requiring team members to recognize their responsibilities and maintain clarity regarding roles, especially when communicating with sponsors. Equally important are strong relationships with sites, which serve as critical partners in clinical trial success. Establishing robust collaboration with sites moves interactions beyond mere transactions, fostering genuine partnerships that drive successful startup outcomes.
Key Challenges Companies Face During Startup
The clinical trial startup phase presents significant complexity and independence, particularly in global environments where regulatory requirements, ethics committee approvals, and contract negotiations differ across countries and regions. Clear understanding of startup timelines and local regulatory landscapes is essential to maintain efficiency and mitigate delays. Clear alignment among sponsors, CROs, and internal groups such as regulatory, legal, clinical operations, and feasibility is essential. When expectations, responsibilities, and priorities are not well defined, trial delays tend to increase.
Site readiness and engagement require careful assessment beyond feasibility on paper. Real-world constraints such as staffing shortages, competing studies, and slow contract execution must be identified early. Effective contingency planning, including backup site identification and robust site activation timelines, ensures baseline activation rates are maintained throughout the trial.
Proactive risk management forms the foundation of successful startup operations. Early anticipation of challenges, informed by comprehensive knowledge of local regulatory requirements, prevents reactive approaches and minimizes cost impact. Strategic startup units must foster innovation, collaboration, and value creation, transforming the risk-heavy startup phase into a controlled, predictive, and proactive process.
As we conclude another illuminating episode of Phase Forward, we find ourselves at the crossroads of science and progress. Remember that behind the jargon and statistics, lies stories of unwavering commitment, meticulous observation, and the pursuit of evidence that shapes our understanding of health and disease. Stay at the forefront of knowledge and innovation and follow Phase Forward on your preferred platform. My name is Valerie Coveney. Thank you for joining us. Until next time.
